It may not be needed to get approval but perhaps required post approval. I just don't see the FDA saying no on a positive outcome, conducted by the VA against a disease with so few options. Then again, if we don't resolve the patent problems I don't see them adding it to the US label. The ROW will benefit from additional indications.
News 
Market Data 
Discover 
